101
|
Zheng F, von Spreckelsen N, Zhang X, Stavrinou P, Timmer M, Dohmen C, Goldbrunner R, Cao F, Zhang Q, Ran Q, Li G, Fan R, Yao S, Krischek B. Should preventive antibiotics be used in patients with acute stroke? A systematic review and meta-analysis of randomized controlled trials. PLoS One 2017; 12:e0186607. [PMID: 29049353 PMCID: PMC5648227 DOI: 10.1371/journal.pone.0186607] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2017] [Accepted: 10/04/2017] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Infection is a common complication in acute stroke. Whether or not preventive antibiotics reduce the risk of infection or even lead to a favorable outcome and reduction of mortality after a stroke still remains equivocal. This review was performed to update the current knowledge on the effect and possible benefits of prophylactic antibiotic therapy in patients with stroke. METHODS A systematic review and meta-analysis of preventive antibiotics`effect on the incidence of infection, favorable outcome (mRS≤2) and mortality in patients with acute stroke is performed with relevant randomized controlled trials. RESULTS Six studies were identified, involving 4125 participants. Compared with the control group, the treated groups were significantly less prone to suffer from early overall infections [RR = 0.52, 95%CI (0.39, 0.70), p<0.0001], early pneumonia [RR = 0.64, 95%CI (0.42, 0.96), p = 0.03] and early urinary tract infections [RR = 0.35, 95%CI (0.25, 0.48), p<0.00001]. However, there was no significant difference in overall mortality [RR = 1.07, 95%CI (0.90, 1.27), p = 0.44], early mortality [RR = 0.99, 95%CI (0.78, 1.26), p = 0.92], late mortality [RR = 1.12, 95%CI (0.94, 1.35), p = 0.21] or favorable outcome [RR = 1.00, 95%CI (0.92, 1.08), p = 0.98]. CONCLUSION Although preventive antibiotic treatment did reduce the occurrence of early overall infections, early pneumonia and early urinary tract infection in patients with acute stroke, this advantage was not eventually translated to a favorable outcome and reduction in mortality. Future studies are warranted to identify any subgroup of stroke patients who might benefit from preventive antibiotic treatment.
Collapse
Affiliation(s)
- Feng Zheng
- Department of Neurosurgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
- Department of Neurosurgery, University Hospital of Cologne, Cologne, Germany
- * E-mail: (BK); (FZ)
| | | | - Xintong Zhang
- Department of Neurosurgery, The Second Clinical Medical School of Inner Mongolia University for the Nationalities (Inner Mongolia Forestry General Hospital), Inner Mongolia, China
| | - Pantelis Stavrinou
- Department of Neurosurgery, University Hospital of Cologne, Cologne, Germany
| | - Marco Timmer
- Department of Neurosurgery, University Hospital of Cologne, Cologne, Germany
| | - Christian Dohmen
- Department of Neurology, University Hospital of Cologne, Cologne, Germany
| | - Roland Goldbrunner
- Department of Neurosurgery, University Hospital of Cologne, Cologne, Germany
| | - Fang Cao
- Department of Cerebrovascular Disease, the first affiliated hospital of Zunyi Medical College, Zunyi, Guizhou, China
| | - Qiang Zhang
- Department of Cerebrovascular Disease, the first affiliated hospital of Zunyi Medical College, Zunyi, Guizhou, China
| | - Qishan Ran
- Department of Cerebrovascular Disease, the first affiliated hospital of Zunyi Medical College, Zunyi, Guizhou, China
| | - Gang Li
- Department of Cerebrovascular Disease, the first affiliated hospital of Zunyi Medical College, Zunyi, Guizhou, China
| | - Ruiming Fan
- Department of Cerebrovascular Disease, the first affiliated hospital of Zunyi Medical College, Zunyi, Guizhou, China
| | - Shengtao Yao
- Department of Cerebrovascular Disease, the first affiliated hospital of Zunyi Medical College, Zunyi, Guizhou, China
| | - Boris Krischek
- Department of Neurosurgery, University Hospital of Cologne, Cologne, Germany
- * E-mail: (BK); (FZ)
| |
Collapse
|
102
|
Morotti A, Marini S, Lena UK, Crawford K, Schwab K, Kourkoulis C, Ayres AM, Edip Gurol M, Viswanathan A, Greenberg SM, Anderson CD, Rosand J, Goldstein JN. Significance of admission hypoalbuminemia in acute intracerebral hemorrhage. J Neurol 2017; 264:905-911. [PMID: 28283821 PMCID: PMC7436338 DOI: 10.1007/s00415-017-8451-x] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2017] [Revised: 03/03/2017] [Accepted: 03/04/2017] [Indexed: 01/01/2023]
Abstract
Low levels of serum albumin may increase the risk of infections and mortality in critically ill patients. We tested the hypothesis that admission hypoalbuminemia predicted infectious complications and poor outcome in subjects with acute intracerebral hemorrhage (ICH). We analyzed a single center cohort of ICH patients collected between 1994 and 2015. Pneumonia, urinary tract infection and sepsis were retrospectively identified, according to validated criteria. Serum albumin was measured on admission and hypoalbuminemia was defined as total albumin ≤3.5 g/dL. The association between albumin levels, infections, and mortality at 90 days was tested with multivariable logistic regression analyses. A total of 2010 patients were included (median age 74 years, 54.5% males) of whom 444 (22.1%) had hypoalbuminemia on admission and 763 (38%) died within 90 days. The frequency of pneumonia, urinary tract infection, and sepsis was 19.9, 15.1, and 2.7%, respectively. Hypoalbuminemic patients had lower admission Glasgow coma scale, higher frequency of intraventricular hemorrhage and were more likely to have a history of chronic kidney or liver disease. After adjustment for potential confounders, hypoalbuminemia was an independent predictor of pneumonia [odds ratio (OR) 1.76, 95% confidence interval (CI) 1.34-2.33, p < 0.001] and sepsis (OR 2.29, 95% CI 1.22-4.30, p = 0.010). Low levels of albumin were also independently associated with higher mortality at 90 days (OR 1.78, 95% CI 1.30-2.44, p < 0.001). In conclusion, early hypoalbuminemia is common and predicts poor outcome in ICH patients. Increased susceptibility to pneumonia and sepsis may be the pathophysiological mechanism underlying this association.
Collapse
Affiliation(s)
- Andrea Morotti
- Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, USA.
- J. P. Kistler Stroke Research Center, Harvard Medical School, Massachusetts General Hospital, 175 Cambridge Street, Suite 300, Boston, MA, 02114, USA.
| | - Sandro Marini
- Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, USA
- J. P. Kistler Stroke Research Center, Harvard Medical School, Massachusetts General Hospital, 175 Cambridge Street, Suite 300, Boston, MA, 02114, USA
| | - Umme K Lena
- J. P. Kistler Stroke Research Center, Harvard Medical School, Massachusetts General Hospital, 175 Cambridge Street, Suite 300, Boston, MA, 02114, USA
| | - Katherine Crawford
- J. P. Kistler Stroke Research Center, Harvard Medical School, Massachusetts General Hospital, 175 Cambridge Street, Suite 300, Boston, MA, 02114, USA
| | - Kristin Schwab
- J. P. Kistler Stroke Research Center, Harvard Medical School, Massachusetts General Hospital, 175 Cambridge Street, Suite 300, Boston, MA, 02114, USA
| | - Christina Kourkoulis
- J. P. Kistler Stroke Research Center, Harvard Medical School, Massachusetts General Hospital, 175 Cambridge Street, Suite 300, Boston, MA, 02114, USA
| | - Alison M Ayres
- J. P. Kistler Stroke Research Center, Harvard Medical School, Massachusetts General Hospital, 175 Cambridge Street, Suite 300, Boston, MA, 02114, USA
| | - M Edip Gurol
- J. P. Kistler Stroke Research Center, Harvard Medical School, Massachusetts General Hospital, 175 Cambridge Street, Suite 300, Boston, MA, 02114, USA
| | - Anand Viswanathan
- J. P. Kistler Stroke Research Center, Harvard Medical School, Massachusetts General Hospital, 175 Cambridge Street, Suite 300, Boston, MA, 02114, USA
| | - Steven M Greenberg
- J. P. Kistler Stroke Research Center, Harvard Medical School, Massachusetts General Hospital, 175 Cambridge Street, Suite 300, Boston, MA, 02114, USA
| | - Christopher D Anderson
- Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, USA
- J. P. Kistler Stroke Research Center, Harvard Medical School, Massachusetts General Hospital, 175 Cambridge Street, Suite 300, Boston, MA, 02114, USA
| | - Jonathan Rosand
- Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, USA
- J. P. Kistler Stroke Research Center, Harvard Medical School, Massachusetts General Hospital, 175 Cambridge Street, Suite 300, Boston, MA, 02114, USA
| | - Joshua N Goldstein
- Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, USA
- J. P. Kistler Stroke Research Center, Harvard Medical School, Massachusetts General Hospital, 175 Cambridge Street, Suite 300, Boston, MA, 02114, USA
- Department of Emergency Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, USA
| |
Collapse
|
103
|
Ulm L, Hoffmann S, Nabavi D, Hermans M, Mackert BM, Hamilton F, Schmehl I, Jungehuelsing GJ, Montaner J, Bustamante A, Katan M, Hartmann A, Ebmeyer S, Dinter C, Wiemer JC, Hertel S, Meisel C, Anker SD, Meisel A. The Randomized Controlled STRAWINSKI Trial: Procalcitonin-Guided Antibiotic Therapy after Stroke. Front Neurol 2017; 8:153. [PMID: 28484421 PMCID: PMC5402305 DOI: 10.3389/fneur.2017.00153] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2017] [Accepted: 04/03/2017] [Indexed: 11/17/2022] Open
Abstract
Background Pneumonia is among the most common acute complications after stroke and is associated with poor long-term outcome. Biomarkers may help identifying stroke patients at high risk for developing stroke-associated pneumonia (SAP) and to guide early treatment. Aims This trial investigated whether procalcitonin (PCT) ultrasensitive (PCTus)-guided antibiotic treatment of SAP can improve functional outcome after stroke. Methods In this international, multicenter, randomized, controlled clinical trial with blinded assessment of outcomes, patients with severe ischemic stroke in the middle cerebral artery territory were randomly assigned within 40 h after symptom onset to PCTus-based antibiotic therapy guidance in addition to stroke unit care or standard stroke unit care alone. The primary endpoint was functional outcome at 3 months, defined according to the modified Rankin Scale (mRS) and dichotomized as acceptable (≤4) or unacceptable (≥5). Secondary endpoints included usage of antibiotics, infection rates, days of fever, and mortality. The trial was registered with http://ClinicalTrials.gov (Identifier NCT01264549). Results In the intention-to-treat-analysis based on 227 patients (112 in PCT and 115 in control group), 197 patients completed the 3-month follow-up. Adherence to PCT guidance was 65%. PCT-guided therapy did not improve functional outcome as measured by mRS (odds ratio 0.79; 95% confidence interval 0.45–1.35, p = 0.47). Pneumonia rate and mortality were similar in both groups. Days with fever tended to be lower (p = 0.055), whereas total number of days treated with antibiotics were higher (p = 0.004) in PCT compared to control group. A post hoc analysis including all PCT values in the intention-to-treat population demonstrated a significant increase on the first day of infection in patients with pneumonia and sepsis compared to patients with urinary tract infections or without infections (p < 0.0001). Conclusion PCTus-guided antibiotic therapy did not improve functional outcome at 3 months after severe ischemic stroke. PCT is a promising biomarker for early detection of pneumonia and sepsis in acute stroke patients.
Collapse
Affiliation(s)
- Lena Ulm
- NeuroCure Clinical Research Center, Charité - Universitaetsmedizin Berlin, Berlin, Germany.,Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia.,Department of Neurology and Center for Stroke Research Berlin, Charité - Universitaetsmedizin Berlin, Berlin, Germany
| | - Sarah Hoffmann
- NeuroCure Clinical Research Center, Charité - Universitaetsmedizin Berlin, Berlin, Germany.,Department of Neurology and Center for Stroke Research Berlin, Charité - Universitaetsmedizin Berlin, Berlin, Germany
| | - Darius Nabavi
- Department of Neurology, Vivantes Klinikum Neukoelln, Berlin, Germany
| | - Marcella Hermans
- Department of Neurology, Vivantes Klinikum Neukoelln, Berlin, Germany
| | | | - Frank Hamilton
- Department of Neurology, Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany
| | - Ingo Schmehl
- Department of Neurology, Unfallkrankenhaus Berlin, Berlin, Germany
| | - Gerhard-Jan Jungehuelsing
- Department of Neurology and Center for Stroke Research Berlin, Charité - Universitaetsmedizin Berlin, Berlin, Germany.,Department of Neurology, Juedisches Krankenhaus Berlin, Berlin, Germany
| | - Joan Montaner
- Neurovascular Research Laboratory, Institut de Recerca, Hospital Universitari Vall d'Hebrón, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Alejandro Bustamante
- Neurovascular Research Laboratory, Institut de Recerca, Hospital Universitari Vall d'Hebrón, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Mira Katan
- Department of Neurology, Universitaetsspital Zuerich, Zurich, Switzerland
| | - Andreas Hartmann
- Department of Neurology, Klinikum Frankfurt Oder, Frankfurt Oder, Germany
| | - Stefan Ebmeyer
- Thermo Fisher Scientific BRAHMS GmbH, Hennigsdorf, Germany
| | | | - Jan C Wiemer
- Thermo Fisher Scientific BRAHMS GmbH, Hennigsdorf, Germany
| | - Sabine Hertel
- Thermo Fisher Scientific BRAHMS GmbH, Hennigsdorf, Germany
| | - Christian Meisel
- Department of Immunology, Charité - Universitaetsmedizin Berlin, Berlin, Germany
| | - Stefan D Anker
- Division of Innovative Clinical Trials, Department of Cardiology and Pneumology, University Medical Centre Goettingen, Goettingen, Germany.,Centre for Clinical and Basic Research, IRCCS, Rome, Italy
| | - Andreas Meisel
- NeuroCure Clinical Research Center, Charité - Universitaetsmedizin Berlin, Berlin, Germany.,Department of Neurology and Center for Stroke Research Berlin, Charité - Universitaetsmedizin Berlin, Berlin, Germany
| |
Collapse
|
104
|
Otite FO, Khandelwal P, Malik AM, Chaturvedi S, Sacco RL, Romano JG. Ten-Year Temporal Trends in Medical Complications After Acute Intracerebral Hemorrhage in the United States. Stroke 2017; 48:596-603. [DOI: 10.1161/strokeaha.116.015746] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2016] [Revised: 01/22/2017] [Accepted: 01/23/2017] [Indexed: 11/16/2022]
Abstract
Background and Purpose—
Data on medical complications after intracerebral hemorrhage (ICH) are sparse. We assessed trends in the prevalence of urinary tract infection, pneumonia, sepsis, deep venous thrombosis (DVT), pulmonary embolism, acute renal failure (ARF), and acute myocardial infarction after ICH in the United States.
Methods—
A total of 575 211 adult ICH cases were identified from the 2004 to 2013 Nationwide Inpatient Sample. Weighted complication risks were computed by sex and mechanical ventilation status. Multivariate models were used to evaluate trends in complications and assess their association with in-hospital mortality, cost, and length of stay.
Results—
Overall risks of urinary tract infection, pneumonia, sepsis, DVT, pulmonary embolism, ARF, and acute myocardial infarction after ICH were 14.8%, 7.8%, 4.1%, 2.7%, 0.7%, 8.2%, and 2.0%, respectively, but risk differed by sex and mechanical ventilation status. From 2004 to 2013, odds of DVT and ARF increased, whereas odds of pneumonia, sepsis, and mortality declined over time. All complications were associated with >2.5-day increase in length of stay and >$8000 increase in cost. ARF and acute myocardial infarction were associated with increased mortality in all patients; sepsis and pneumonia were associated with increased mortality only in nonmechanical ventilation patients, whereas urinary tract infection and DVT were associated with reduced mortality in all patients.
Conclusions—
Despite significant mortality reduction, ARF and DVT risk after ICH have increased, whereas odds of sepsis and pneumonia have declined over the last decade. All complications were associated with increased cost and length of stay, but their associations with mortality were variable, likely due in part to survival bias. Innovative strategies are needed to prevent ICH-associated medical complications.
Collapse
Affiliation(s)
- Fadar Oliver Otite
- From the Department of Neurology, University of Miami Miller School of Medicine, FL
| | - Priyank Khandelwal
- From the Department of Neurology, University of Miami Miller School of Medicine, FL
| | - Amer M. Malik
- From the Department of Neurology, University of Miami Miller School of Medicine, FL
| | - Seemant Chaturvedi
- From the Department of Neurology, University of Miami Miller School of Medicine, FL
| | - Ralph L. Sacco
- From the Department of Neurology, University of Miami Miller School of Medicine, FL
| | - Jose G. Romano
- From the Department of Neurology, University of Miami Miller School of Medicine, FL
| |
Collapse
|
105
|
Zhang R, Ji R, Pan Y, Jiang Y, Liu G, Wang Y, Wang Y. External Validation of the Prestroke Independence, Sex, Age, National Institutes of Health Stroke Scale Score for Predicting Pneumonia After Stroke Using Data From the China National Stroke Registry. J Stroke Cerebrovasc Dis 2016; 26:938-943. [PMID: 27988203 DOI: 10.1016/j.jstrokecerebrovasdis.2016.10.043] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2016] [Revised: 10/14/2016] [Accepted: 10/31/2016] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND AND PURPOSE Pneumonia is an important risk factor for mortality and morbidity after stroke. The Prestroke Independence, Sex, Age, National Institutes of Health Stroke Scale (ISAN) score was shown to be a useful tool for predicting stroke-associated pneumonia based on UK multicenter cohort study. We aimed to externally validate the score using data from the China National Stroke Registry (CNSR). METHODS Eligible patients with acute ischemic stroke (AIS) and intracerebral hemorrhage (ICH) in the CNSR from 2007 to 2008 were included. The area under the receiver operating characteristic (AUC) curve was used to evaluate discrimination. The Hosmer-Lemeshow goodness of fit test and Pearson correlation coefficient were performed to assess calibration of the model. RESULTS A total of 19,333 patients (AIS = 14400; ICH = 4933) were included and the overall pneumonia rate was 12.7%. The AUC was .76 (95% confidence interval [CI]: .75-.78) for the subgroup of AIS and .70 (95% CI: .68-.72) for the subgroup of ICH. The Hosmer-Lemeshow test showed the ISAN score with the good calibration for AIS and ICH (P = .177 and .405, respectively). The plot of observed versus predicted pneumonia rates suggested higher correlation for patients with AIS than with ICH (Pearson correlation coefficient = .99 and .83, respectively). CONCLUSIONS The ISAN score was a useful tool for predicting in-hospital pneumonia after acute stroke, especially for patients with AIS. Further validations need to be done in different populations.
Collapse
Affiliation(s)
- Runhua Zhang
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing, China; Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
| | - Ruijun Ji
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing, China; Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
| | - Yuesong Pan
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing, China; Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
| | - Yong Jiang
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing, China; Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
| | - Gaifen Liu
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing, China; Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
| | - Yilong Wang
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing, China; Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China.
| | - Yongjun Wang
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing, China; Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China.
| |
Collapse
|
106
|
Ferdinand P, Roffe C. Hypoxia after stroke: a review of experimental and clinical evidence. EXPERIMENTAL & TRANSLATIONAL STROKE MEDICINE 2016; 8:9. [PMID: 27980710 PMCID: PMC5143450 DOI: 10.1186/s13231-016-0023-0] [Citation(s) in RCA: 75] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 08/24/2016] [Accepted: 11/26/2016] [Indexed: 02/08/2023]
Abstract
Background Hypoxia is a common occurrence following stroke and associated with poor clinical and functional outcomes. Normal oxygen physiology is a finely controlled mechanism from the oxygenation of haemoglobin in the pulmonary capillaries to its dissociation and delivery in the tissues. In no organ is this process more important than the brain, which has a number of vascular adaptions to be able to cope with a certain threshold of hypoxia, beyond which further disruption of oxygen delivery potentially leads to devastating consequences. Hypoxia following stroke is common and is often attributed to pneumonia, aspiration and respiratory muscle dysfunction, with sleep apnoea syndromes, pulmonary embolism and cardiac failure being less common but important treatable causes. As well as treating the underlying cause, oxygen therapy is a vital element to correcting hypoxia, but excessive use can itself cause molecular and clinical harm. As cerebral vascular occlusion completely obliterates oxygen delivery to its target tissue, the use of supplemental oxygen, even when not hypoxic, would seem a reasonable solution to try and correct this deficit, but to date randomised clinical trials have not shown benefit. Conclusion Whilst evidence for the use of supplemental oxygen therapy is currently lacking, it is vital to rapidly identify and treat all causes of hypoxia in the acute stroke patient, as a failure to will lead to poorer clinical outcomes. The full results of a large randomised trial looking at the use of supplemental oxygen therapy are currently pending.
Collapse
Affiliation(s)
| | - Christine Roffe
- Stroke Research in Stoke, Institute for Applied Clinical Studies, Keele University, Keele, Staffordshire UK
| |
Collapse
|
107
|
Kalra L, Hodsoll J, Irshad S, Smithard D, Manawadu D. Comparison of the diagnostic utility of physician-diagnosed with algorithm-defined stroke-associated pneumonia. J Neurol Neurosurg Psychiatry 2016; 87:1163-1168. [PMID: 27432801 DOI: 10.1136/jnnp-2016-313508] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/09/2016] [Accepted: 06/30/2016] [Indexed: 11/03/2022]
Abstract
OBJECTIVE Diagnosing stroke-associated pneumonia (SAP) is challenging and may result in inappropriate antibiotic use or confound research outcomes. This study evaluates the diagnostic accuracy of algorithm-defined versus physician-diagnosed SAP in 1088 patients who had dysphagic acute stroke from 37 UK stroke units between 21 April 2008 and 17 May 2014. METHODS SAP in the first 14 days was diagnosed by a criteria-based algorithm applied to blinded patient data and independently by treating physicians. Patients in whom diagnoses differed were reassigned following blinded adjudication of individual patient records. The sensitivity, specificity, positive predictive value (PPV) and diagnostic OR of algorithmic and physician diagnosis of SAP were assessed using adjudicated SAP as the reference standard. Agreement was assessed using the κ statistic. RESULTS Physicians diagnosed SAP in 176/1088 (16%) and the algorithm in 123/1088 (11.3%) patients. Diagnosis agreed in 885/1088 (81.3%) patients (κ 0.22 (95% CI 0.14 to 0.29)). On a blinded review, 129/1088 (11.8%) patients were adjudicated as patients with SAP. The algorithm and the physicians had high specificity (97% (95% CI 96% to 98%) and 90% (95% CI 88% to 92%), respectively) but only moderate sensitivity (72% (95% CI 64% to 80%) and 65% (95% CI 56% to 73%), respectively) in diagnosing SAP. The algorithm showed better PPV (76% (95% CI 67% to 83%) vs 48% (95% CI 40% to 55%)), diagnostic OR (80 (95% CI 42 to 136) vs 18 (95% CI 12 to 27)) and agreement (κ 0.70 (95% CI 0.63 to 0.78) vs 0.48 (95% CI 0.41 to 0.54)) than physician diagnosis with adjudicated SAP. CONCLUSIONS Algorithm-based approaches can standardise SAP diagnosis for clinical practice and research. TRIAL REGISTRATION NUMBER ISRCTN37118456; Post-results.
Collapse
Affiliation(s)
- Lalit Kalra
- Department of Basic and Clinical Neurosciences, Institute of Psychiatry, Psychology and Neurosciences, King's College London, London, UK
| | - John Hodsoll
- Biostatistics Department, NIHR Biomedical Research Centre for Mental Health and Institute of Psychiatry, Psychology and Neurosciences, King's College London, London, UK
| | - Saddif Irshad
- Department of Basic and Clinical Neurosciences, Institute of Psychiatry, Psychology and Neurosciences, King's College London, London, UK
| | | | - Dulka Manawadu
- King's College Hospital NHS Foundation Trust, London, UK
| | | |
Collapse
|
108
|
Sari IM, Soertidewi L, Yokota C, Kikuno M, Koga M, Toyoda K. Comparison of Characteristics of Stroke-Associated Pneumonia in Stroke Care Units in Indonesia and Japan. J Stroke Cerebrovasc Dis 2016; 26:280-285. [PMID: 27746080 DOI: 10.1016/j.jstrokecerebrovasdis.2016.09.018] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2016] [Revised: 08/22/2016] [Accepted: 09/11/2016] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Pneumonia is one of the most common medical complications after stroke. Incidence and risk factor analyses of stroke-associated pneumonia (SAP) in stroke care units (SCUs) are limited. SAP incidence comparisons across countries can identify the most effective treatment to reduce this incidence. METHODS This was a retrospective study including consecutive patients with acute stroke in SCUs in 2 hospitals: 105 patients (mean age 78.2 ± 5.8) from the National Cerebral and Cardiovascular Center (NCVC) in Osaka, Japan (from July to August 2015), and 105 patients (mean age 60 ± 5.8) from the National Brain Centre (NBC) Hospital in Jakarta, Indonesia (from May to September 2015). We used descriptive statistics and a logistic regression model for statistical analysis. RESULTS The incidence of SAP in the SCU NBC Hospital was higher than that in the SCU NCVC (22.9% versus 12.4%, P = .0466). In the SCU NBC Hospital, dysphagia (odds ratio [OR] 15.20, 95% confidence interval [CI] 1.77-130.73) and severe neurological deficits on admission (OR 5.31, 95% CI 1.60-17.60) were significantly associated with SAP, whereas in the SCU NCVC, dysphagia (OR 14.42, 95% CI 2.34-88.98) and diabetes mellitus (OR 7.16, 95% CI 1.27-40.18) were the risk factors. When the patients of both hospitals were analyzed together, severe neurological deficits on admission (OR 3.36, 95% CI 1.31-8.64) and dysphagia (OR 12.62, 95% CI 3.75-42.45) were significant determinants for developing SAP. CONCLUSIONS The incidence of SAP was higher in the Indonesian hospital than in the Japanese one. Our findings support other epidemiological data of a high incidence of SAP with severe neurological deficits on admission and dysphagia in an SCU setting.
Collapse
Affiliation(s)
| | | | - Chiaki Yokota
- Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.
| | - Muneaki Kikuno
- Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan
| | - Masatoshi Koga
- Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan
| | - Kazunori Toyoda
- Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan
| |
Collapse
|
109
|
Abstract
Infections, in particular pneumonia, are common complications in patients with acute stroke and are associated with a less favorable neurologic and functional outcome. Patients with severe stroke and dysphagia are at highest risk of infection. Experimental and clinical data suggest stroke-induced immunodeficiency as a major factor contributing to the high incidence of infection after stroke. Preclinical studies support the potential benefit of preventive antibiotic therapy in acute stroke for lowering the incidence of infection and improving clinical outcome. Several smaller clinical trials on preventive antibiotic therapy in patients with stroke conducted during the last 10 years yielded inconclusive results. Recently, 2 large, open-label, controlled trials failed to demonstrate an improved clinical outcome after preventive antibiotic therapy in patients with acute stroke treated in specialized stroke units. In the "Preventive Antibiotics in Stroke Study", antibiotic therapy lowered the rate of infection but did not influence outcome. In the STROKE-INF study, performed in patients with dysphagia after stroke, antibiotic therapy did not lower the incidence of pneumonia and had no prognostic significance. At present, preventive antibiotic therapy cannot be recommended as a therapeutic option for acute stroke.
Collapse
Affiliation(s)
- Stefan Schwarz
- Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany.
| |
Collapse
|
110
|
Kalra L, Hodsoll J, Irshad S, Smithard D, Manawadu D. Association between nasogastric tubes, pneumonia, and clinical outcomes in acute stroke patients. Neurology 2016; 87:1352-9. [PMID: 27566745 DOI: 10.1212/wnl.0000000000003151] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2016] [Accepted: 05/23/2016] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To investigate whether nasogastric tubes (NGTs) increase poststroke pneumonia (PSP), mortality, or poor outcomes in nil-by-mouth acute stroke patients. METHODS This study analyzed prespecified outcomes of PSP at 14 days and mortality and function measured by the modified Rankin Scale at 90 days in 1,217 nil-by-mouth stroke patients at ≤48 hours of symptom onset in a multicenter randomized controlled trial of preventive antibiotics between April 21, 2008, and May 17, 2014. Generalized mixed models adjusted for age, comorbidities, stroke type and severity, and quality of care were used. No patients were lost to follow-up at 14 days, and 36 (3%) were lost at 90 days. RESULTS Patients with NGT (298 of 1,217 [24.4%]) had more severe strokes (median NIH Stroke Scale score 17 vs 14, p = 0.0001) and impaired consciousness (39% vs 28%, p = 0.001). NGT did not increase PSP (43 of 298 [14.4%] vs 80 of 790 [10.1%], adjusted odds ratio [OR] 1.26 [95% confidence interval (CI) 0.78-2.03], p = 0.35) or 14- and 90-day mortality (33 of 298 [11.1%] vs 78 of 790 [9.9%], adjusted OR 1.10 [95% CI 0.67-1.78], p = 0.71; and 79 of 298 [26.5%] vs 152 of 790 [19.2%], adjusted OR 0.95 [95% CI 0.67-1.33], p = 0.75, respectively). Ninety-day modified Rankin Scale score distribution was comparable between groups (adjusted OR 1.14 [95% CI 0.87-1.56], p = 0.08). PSP independently increased 90-day mortality (40 of 123 [32.5%] vs 191 of 965 [19.8%], adjusted OR 1.71 [95% CI 1.11-2.65], p = 0.015) and was not prevented by antibiotics in patients with NGT (adjusted OR 1.1 [95% CI 0.89-1.54], p = 0.16). CONCLUSIONS Early NGT does not increase PSP incidence, mortality, or poor functional outcomes and can be used safely in acute stroke patients.
Collapse
Affiliation(s)
- Lalit Kalra
- From the Department of Basic and Clinical Neurosciences (L.K., S.I.), Institute of Psychiatry, Psychology and Neurosciences, and Biostatistics Department (J.H.), NIHR Biomedical Research Centre for Mental Health and Institute of Psychiatry, Psychology and Neurosciences, King's College London, UK; University of Kent (D.S.), Canterbury, UK; and King's College Hospital NHS Foundation Trust, London, UK (D.M.).
| | - John Hodsoll
- From the Department of Basic and Clinical Neurosciences (L.K., S.I.), Institute of Psychiatry, Psychology and Neurosciences, and Biostatistics Department (J.H.), NIHR Biomedical Research Centre for Mental Health and Institute of Psychiatry, Psychology and Neurosciences, King's College London, UK; University of Kent (D.S.), Canterbury, UK; and King's College Hospital NHS Foundation Trust, London, UK (D.M.)
| | - Saddif Irshad
- From the Department of Basic and Clinical Neurosciences (L.K., S.I.), Institute of Psychiatry, Psychology and Neurosciences, and Biostatistics Department (J.H.), NIHR Biomedical Research Centre for Mental Health and Institute of Psychiatry, Psychology and Neurosciences, King's College London, UK; University of Kent (D.S.), Canterbury, UK; and King's College Hospital NHS Foundation Trust, London, UK (D.M.)
| | - David Smithard
- From the Department of Basic and Clinical Neurosciences (L.K., S.I.), Institute of Psychiatry, Psychology and Neurosciences, and Biostatistics Department (J.H.), NIHR Biomedical Research Centre for Mental Health and Institute of Psychiatry, Psychology and Neurosciences, King's College London, UK; University of Kent (D.S.), Canterbury, UK; and King's College Hospital NHS Foundation Trust, London, UK (D.M.)
| | - Dulka Manawadu
- From the Department of Basic and Clinical Neurosciences (L.K., S.I.), Institute of Psychiatry, Psychology and Neurosciences, and Biostatistics Department (J.H.), NIHR Biomedical Research Centre for Mental Health and Institute of Psychiatry, Psychology and Neurosciences, King's College London, UK; University of Kent (D.S.), Canterbury, UK; and King's College Hospital NHS Foundation Trust, London, UK (D.M.)
| | | |
Collapse
|
111
|
Statin Medication Use and Nosocomial Infection Risk in the Acute Phase of Stroke. J Stroke Cerebrovasc Dis 2016; 25:2360-7. [PMID: 27292907 DOI: 10.1016/j.jstrokecerebrovasdis.2016.05.033] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2016] [Revised: 05/21/2016] [Accepted: 05/23/2016] [Indexed: 11/22/2022] Open
Abstract
GOAL Statins have immunomodulatory and peripheral anti-inflammatory properties that are independent of their lipid-lowering action. Whether these properties reduce the risk for developing poststroke infection is debated in clinical literature. We estimated the risk for developing nosocomial poststroke infection based on statin exposure in patients aged 18 or older hospitalized for ischemic stroke. MATERIALS AND METHODS A consecutive sample of acute care hospital electronic medical records was retrospectively analyzed. Patients were assigned to the exposed cohort either when statin use preceded infection or statin medication was used, but no infection developed. The unexposed cohort included patients not on statins or initiating statins after infection developed. The association of statin exposure with infection was examined with conditional logistic regression adjusted for poststroke infection risk factors. Cochran-Mantel-Haenszel analyses examined the association of statin exposure and infection status within strata of binary predictor variables that increased infection risk. FINDINGS Up to 1612 records were analyzed: 1151 in the exposed cohort and 461 in the unexposed cohort. Infection developed in 20% of the statin-exposed patients and in 41% of the statin-unexposed patients (P < .001). Exposure to statins reduced odds for developing nosocomial infection by 58% over no exposure (adjusted odds ratio = .418, P < .001). Statins lowered the infection risk for both sexes, patients with a nasogastric tube, and patients with dysphagia (P < .05). Statins did not change infection risk for patients with endotracheal intubation. CONCLUSIONS In patients with ischemic stroke and without endotracheal intubation, statin medications were associated with reduced risk of nosocomial infections.
Collapse
|
112
|
Kishore AK, Vail A, Bray BD, Chamorro A, Napoli MD, Kalra L, Langhorne P, Montaner J, Roffe C, Rudd AG, Tyrrell PJ, van de Beek D, Woodhead M, Meisel A, Smith CJ. Clinical risk scores for predicting stroke-associated pneumonia: A systematic review. Eur Stroke J 2016; 1:76-84. [PMID: 31008268 DOI: 10.1177/2396987316651759] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2016] [Accepted: 05/03/2016] [Indexed: 11/16/2022] Open
Abstract
Purpose Several risk stratification scores for predicting stroke-associated pneumonia have been derived. We aimed to evaluate the performance and clinical usefulness of such scores for predicting stroke-associated pneumonia. Method A systematic literature review was undertaken in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement, with application of the Quality Assessment of Diagnostic Accuracy-2 tool. Published studies of hospitalised adults with ischaemic stroke, intracerebral haemorrhage, or both, which derived and validated an integer-based clinical risk score, or externally validated an existing score to predict occurrence of stroke-associated pneumonia, were considered and independently screened for inclusion by two reviewers. Findings We identified nine scores, from eight derivation cohorts. Age was a component of all scores, and the NIHSS score in all except one. Six scores were internally validated and five scores were externally validated. The A2DS2 score (Age, Atrial fibrillation, Dysphagia, Severity [NIHSS], Sex) was the most externally validated in 8 independent cohorts. Performance measures were reported for eight scores. Discrimination tended to be more variable in the external validation cohorts (C statistic 0.67-0.83) than the derivation cohorts (C statistic 0.74-0.85). Discussion Overall, discrimination and calibration were similar between the different scores. No study evaluated influence on clinical decision making or prognosis. Conclusion The clinical prediction scores varied in their simplicity of use and were comparable in performance. Utility of such scores for preventive intervention trials and in clinical practice remains uncertain and requires further study.
Collapse
Affiliation(s)
- Amit K Kishore
- Stroke and Vascular Research Centre, University of Manchester, Institute of Cardiovascular Sciences; Greater Manchester Neurosciences Centre, Salford Royal NHS Foundation Trust, Salford, UK
| | - Andy Vail
- Centre for Biostatistics, University of Manchester, Salford Royal Foundation Trust, Salford, UK
| | | | - Angel Chamorro
- Comprehensive Stroke Centre, Department of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain
| | - Mario Di Napoli
- Neurological Service, San Camillo de' Lellis General Hospital, Rieti, Italy
| | - Lalit Kalra
- Clinical Neurosciences, King's College Hospital NHS Foundation Trust London, London, UK
| | - Peter Langhorne
- Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK
| | - Joan Montaner
- Laboratorio de Investigación Neurovascular, Unidad Neurovascular, Servicio de Neurología Hospital Vall d' Hebron, Barcelona, Spain.,IBIS Stroke Programme, Hospital Virgen del Rocio, Sevilla, Spain
| | - Christine Roffe
- Keele University Institute for Science and Technology in Medicine, Guy Hilton Research Centre, Stoke-on-Trent, UK
| | - Anthony G Rudd
- Department of Health and Social Care, King's College, London, UK
| | - Pippa J Tyrrell
- Stroke and Vascular Research Centre, University of Manchester, Institute of Cardiovascular Sciences; Greater Manchester Neurosciences Centre, Salford Royal NHS Foundation Trust, Salford, UK
| | - Diederik van de Beek
- Department of Neurology, Centre for Infection and Immunity Amsterdam (CINIMA), Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands
| | - Mark Woodhead
- Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK.,Department of Respiratory Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | - Andreas Meisel
- NeuroCure Clinical Research Centre, Centre for Stroke Research Berlin; Department of Neurology, Charité Universitaetsmedizin Berlin, Berlin, Germany
| | - Craig J Smith
- Stroke and Vascular Research Centre, University of Manchester, Institute of Cardiovascular Sciences; Greater Manchester Neurosciences Centre, Salford Royal NHS Foundation Trust, Salford, UK
| |
Collapse
|
113
|
Smith CJ, Horne M, McCracken G, Young D, Clements I, Hulme S, Ardron C, Hamdy S, Vail A, Walls A, Tyrrell PJ. Development and feasibility testing of an oral hygiene intervention for stroke unit care. Gerodontology 2016; 34:110-120. [PMID: 27198495 DOI: 10.1111/ger.12232] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/04/2016] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To develop an oral hygiene complex intervention and evaluate its feasibility in a single UK stroke centre. BACKGROUND Oral hygiene interventions might improve clinical outcomes after stroke but evidence-based practice is lacking. MATERIALS AND METHODS We used a sequential mixed methods approach and developed an oral hygiene complex intervention comprising: (i) web-based education and 'hands-on' practical training for stroke unit nursing staff, (ii) a pragmatic oral hygiene protocol consisting of twice-daily powered (or manual if preferred) brushing with chlorhexidine gel (or non-foaming toothpaste) ± denture care. We evaluated feasibility of (i) the staff education and training and (ii) the oral hygiene protocol in consenting inpatients with confirmed stroke, requiring assistance with at least one aspect of personal care. RESULTS The staff education and training were feasible, acceptable and raised knowledge and awareness. Several barriers to completing the education and training were identified. The oral hygiene protocol was feasible and well-tolerated. 22% of eligible patients screened declined participation in the study. Twenty-nine patients (median age = 78 year; National Institutes of Health Stroke Scale score = 8.5; 73% dentate) were recruited at a median of 7 days from stroke onset. 97% of participants chose the default chlorhexidine-based protocol; the remainder chose the non-foaming toothpaste-based protocol. The mouth hygiene protocol was administered as prescribed on 95% of occasions, over a median duration of 28 days. There were no adverse events attributed to the oral hygiene protocol. CONCLUSION Our oral hygiene complex intervention was feasible in a single UK stroke centre. Further studies to optimise patient selection, model health economics and explore efficacy are now required.
Collapse
Affiliation(s)
- Craig J Smith
- Greater Manchester Comprehensive Stroke Centre, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, Salford, UK.,Stroke and Vascular Centre, Institute of Cardiovascular Sciences, University of Manchester, Manchester, UK
| | - Maria Horne
- Faculty of Health Studies, School of Nursing, University of Bradford, Bradford, UK
| | - Giles McCracken
- School of Dental Sciences, Newcastle University, Newcastle, UK
| | - David Young
- The Greater Manchester School for Dental Care Professionals (MANDCP), Salford, UK
| | - Ian Clements
- Patient, Carer and Public Involvement Group, North West Stroke Research Network, Salford Royal NHS Foundation Trust, Salford, UK
| | - Sharon Hulme
- Stroke and Vascular Centre, Institute of Cardiovascular Sciences, University of Manchester, Manchester, UK
| | - Claire Ardron
- Greater Manchester Comprehensive Stroke Centre, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, Salford, UK
| | - Shaheen Hamdy
- Centre for Gastrointestinal Sciences, Institute of Inflammation and Repair, University of Manchester, Manchester, UK
| | - Andy Vail
- Centre for Biostatistics, Institute of Population Health, University of Manchester, Manchester, UK
| | - Angus Walls
- Edinburgh Dental Institute, University of Edinburgh, Edinburgh, UK
| | - Pippa J Tyrrell
- Greater Manchester Comprehensive Stroke Centre, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, Salford, UK.,Stroke and Vascular Centre, Institute of Cardiovascular Sciences, University of Manchester, Manchester, UK
| |
Collapse
|
114
|
Bath PM, Scutt P, Love J, Clavé P, Cohen D, Dziewas R, Iversen HK, Ledl C, Ragab S, Soda H, Warusevitane A, Woisard V, Hamdy S. Pharyngeal Electrical Stimulation for Treatment of Dysphagia in Subacute Stroke: A Randomized Controlled Trial. Stroke 2016; 47:1562-70. [PMID: 27165955 PMCID: PMC4878285 DOI: 10.1161/strokeaha.115.012455] [Citation(s) in RCA: 90] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2015] [Accepted: 04/04/2016] [Indexed: 11/16/2022]
Abstract
Supplemental Digital Content is available in the text. Background and Purpose— Dysphagia is common after stroke, associated with increased death and dependency, and treatment options are limited. Pharyngeal electric stimulation (PES) is a novel treatment for poststroke dysphagia that has shown promise in 3 pilot randomized controlled trials. Methods— We randomly assigned 162 patients with a recent ischemic or hemorrhagic stroke and dysphagia, defined as a penetration aspiration score (PAS) of ≥3 on video fluoroscopy, to PES or sham treatment given on 3 consecutive days. The primary outcome was swallowing safety, assessed using the PAS, at 2 weeks. Secondary outcomes included dysphagia severity, function, quality of life, and serious adverse events at 6 and 12 weeks. Results— In randomized patients, the mean age was 74 years, male 58%, ischemic stroke 89%, and PAS 4.8. The mean treatment current was 14.8 (7.9) mA and duration 9.9 (1.2) minutes per session. On the basis of previous data, 45 patients (58.4%) randomized to PES seemed to receive suboptimal stimulation. The PAS at 2 weeks, adjusted for baseline, did not differ between the randomized groups: PES 3.7 (2.0) versus sham 3.6 (1.9), P=0.60. Similarly, the secondary outcomes did not differ, including clinical swallowing and functional outcome. No serious adverse device-related events occurred. Conclusions— In patients with subacute stroke and dysphagia, PES was safe but did not improve dysphagia. Undertreatment of patients receiving PES may have contributed to the neutral result. Clinical Trial Registration— URL: http://www.controlled-trials.com. Unique identifier: ISRCTN25681641.
Collapse
Affiliation(s)
- Philip M Bath
- From the Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B., P.S.); Phagenesis, Ltd, Manchester Science Park, United Kingdom (J.L.); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Hospital de Mataró, Universitat Autònoma de Mataró, Spain (P.C.); Stroke Service, Northwick Park Hospital, London, United Kingdom (D.C.); Department of Neurology, University Hospital Münster, Germany (R.D.); Department of Neurology, Glostrup Hospital and University of Copenhagen, Denmark (H.K.I.); Schoen Klinik Bad Aibling, Bad Aibling, Germany (C.L.); Stroke Service, Poole Hospital, Poole, United Kingdom (S.R.); Neurology Clinic, Bad Neustadt, Germany (H.S.); Acute Stroke Unit, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom (A.W.); Unité de la voix et de la deglutition, Service ORL CHU de Toulouse, Octogone Lordat Université Toulouse Mirail, France (V.W.); and Centre for Gastrointestinal Sciences, University of Manchester, United Kingdom (S.H.).
| | - Polly Scutt
- From the Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B., P.S.); Phagenesis, Ltd, Manchester Science Park, United Kingdom (J.L.); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Hospital de Mataró, Universitat Autònoma de Mataró, Spain (P.C.); Stroke Service, Northwick Park Hospital, London, United Kingdom (D.C.); Department of Neurology, University Hospital Münster, Germany (R.D.); Department of Neurology, Glostrup Hospital and University of Copenhagen, Denmark (H.K.I.); Schoen Klinik Bad Aibling, Bad Aibling, Germany (C.L.); Stroke Service, Poole Hospital, Poole, United Kingdom (S.R.); Neurology Clinic, Bad Neustadt, Germany (H.S.); Acute Stroke Unit, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom (A.W.); Unité de la voix et de la deglutition, Service ORL CHU de Toulouse, Octogone Lordat Université Toulouse Mirail, France (V.W.); and Centre for Gastrointestinal Sciences, University of Manchester, United Kingdom (S.H.)
| | - Jo Love
- From the Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B., P.S.); Phagenesis, Ltd, Manchester Science Park, United Kingdom (J.L.); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Hospital de Mataró, Universitat Autònoma de Mataró, Spain (P.C.); Stroke Service, Northwick Park Hospital, London, United Kingdom (D.C.); Department of Neurology, University Hospital Münster, Germany (R.D.); Department of Neurology, Glostrup Hospital and University of Copenhagen, Denmark (H.K.I.); Schoen Klinik Bad Aibling, Bad Aibling, Germany (C.L.); Stroke Service, Poole Hospital, Poole, United Kingdom (S.R.); Neurology Clinic, Bad Neustadt, Germany (H.S.); Acute Stroke Unit, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom (A.W.); Unité de la voix et de la deglutition, Service ORL CHU de Toulouse, Octogone Lordat Université Toulouse Mirail, France (V.W.); and Centre for Gastrointestinal Sciences, University of Manchester, United Kingdom (S.H.)
| | - Pere Clavé
- From the Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B., P.S.); Phagenesis, Ltd, Manchester Science Park, United Kingdom (J.L.); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Hospital de Mataró, Universitat Autònoma de Mataró, Spain (P.C.); Stroke Service, Northwick Park Hospital, London, United Kingdom (D.C.); Department of Neurology, University Hospital Münster, Germany (R.D.); Department of Neurology, Glostrup Hospital and University of Copenhagen, Denmark (H.K.I.); Schoen Klinik Bad Aibling, Bad Aibling, Germany (C.L.); Stroke Service, Poole Hospital, Poole, United Kingdom (S.R.); Neurology Clinic, Bad Neustadt, Germany (H.S.); Acute Stroke Unit, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom (A.W.); Unité de la voix et de la deglutition, Service ORL CHU de Toulouse, Octogone Lordat Université Toulouse Mirail, France (V.W.); and Centre for Gastrointestinal Sciences, University of Manchester, United Kingdom (S.H.)
| | - David Cohen
- From the Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B., P.S.); Phagenesis, Ltd, Manchester Science Park, United Kingdom (J.L.); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Hospital de Mataró, Universitat Autònoma de Mataró, Spain (P.C.); Stroke Service, Northwick Park Hospital, London, United Kingdom (D.C.); Department of Neurology, University Hospital Münster, Germany (R.D.); Department of Neurology, Glostrup Hospital and University of Copenhagen, Denmark (H.K.I.); Schoen Klinik Bad Aibling, Bad Aibling, Germany (C.L.); Stroke Service, Poole Hospital, Poole, United Kingdom (S.R.); Neurology Clinic, Bad Neustadt, Germany (H.S.); Acute Stroke Unit, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom (A.W.); Unité de la voix et de la deglutition, Service ORL CHU de Toulouse, Octogone Lordat Université Toulouse Mirail, France (V.W.); and Centre for Gastrointestinal Sciences, University of Manchester, United Kingdom (S.H.)
| | - Rainer Dziewas
- From the Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B., P.S.); Phagenesis, Ltd, Manchester Science Park, United Kingdom (J.L.); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Hospital de Mataró, Universitat Autònoma de Mataró, Spain (P.C.); Stroke Service, Northwick Park Hospital, London, United Kingdom (D.C.); Department of Neurology, University Hospital Münster, Germany (R.D.); Department of Neurology, Glostrup Hospital and University of Copenhagen, Denmark (H.K.I.); Schoen Klinik Bad Aibling, Bad Aibling, Germany (C.L.); Stroke Service, Poole Hospital, Poole, United Kingdom (S.R.); Neurology Clinic, Bad Neustadt, Germany (H.S.); Acute Stroke Unit, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom (A.W.); Unité de la voix et de la deglutition, Service ORL CHU de Toulouse, Octogone Lordat Université Toulouse Mirail, France (V.W.); and Centre for Gastrointestinal Sciences, University of Manchester, United Kingdom (S.H.)
| | - Helle K Iversen
- From the Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B., P.S.); Phagenesis, Ltd, Manchester Science Park, United Kingdom (J.L.); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Hospital de Mataró, Universitat Autònoma de Mataró, Spain (P.C.); Stroke Service, Northwick Park Hospital, London, United Kingdom (D.C.); Department of Neurology, University Hospital Münster, Germany (R.D.); Department of Neurology, Glostrup Hospital and University of Copenhagen, Denmark (H.K.I.); Schoen Klinik Bad Aibling, Bad Aibling, Germany (C.L.); Stroke Service, Poole Hospital, Poole, United Kingdom (S.R.); Neurology Clinic, Bad Neustadt, Germany (H.S.); Acute Stroke Unit, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom (A.W.); Unité de la voix et de la deglutition, Service ORL CHU de Toulouse, Octogone Lordat Université Toulouse Mirail, France (V.W.); and Centre for Gastrointestinal Sciences, University of Manchester, United Kingdom (S.H.)
| | - Christian Ledl
- From the Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B., P.S.); Phagenesis, Ltd, Manchester Science Park, United Kingdom (J.L.); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Hospital de Mataró, Universitat Autònoma de Mataró, Spain (P.C.); Stroke Service, Northwick Park Hospital, London, United Kingdom (D.C.); Department of Neurology, University Hospital Münster, Germany (R.D.); Department of Neurology, Glostrup Hospital and University of Copenhagen, Denmark (H.K.I.); Schoen Klinik Bad Aibling, Bad Aibling, Germany (C.L.); Stroke Service, Poole Hospital, Poole, United Kingdom (S.R.); Neurology Clinic, Bad Neustadt, Germany (H.S.); Acute Stroke Unit, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom (A.W.); Unité de la voix et de la deglutition, Service ORL CHU de Toulouse, Octogone Lordat Université Toulouse Mirail, France (V.W.); and Centre for Gastrointestinal Sciences, University of Manchester, United Kingdom (S.H.)
| | - Suzanne Ragab
- From the Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B., P.S.); Phagenesis, Ltd, Manchester Science Park, United Kingdom (J.L.); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Hospital de Mataró, Universitat Autònoma de Mataró, Spain (P.C.); Stroke Service, Northwick Park Hospital, London, United Kingdom (D.C.); Department of Neurology, University Hospital Münster, Germany (R.D.); Department of Neurology, Glostrup Hospital and University of Copenhagen, Denmark (H.K.I.); Schoen Klinik Bad Aibling, Bad Aibling, Germany (C.L.); Stroke Service, Poole Hospital, Poole, United Kingdom (S.R.); Neurology Clinic, Bad Neustadt, Germany (H.S.); Acute Stroke Unit, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom (A.W.); Unité de la voix et de la deglutition, Service ORL CHU de Toulouse, Octogone Lordat Université Toulouse Mirail, France (V.W.); and Centre for Gastrointestinal Sciences, University of Manchester, United Kingdom (S.H.)
| | - Hassan Soda
- From the Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B., P.S.); Phagenesis, Ltd, Manchester Science Park, United Kingdom (J.L.); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Hospital de Mataró, Universitat Autònoma de Mataró, Spain (P.C.); Stroke Service, Northwick Park Hospital, London, United Kingdom (D.C.); Department of Neurology, University Hospital Münster, Germany (R.D.); Department of Neurology, Glostrup Hospital and University of Copenhagen, Denmark (H.K.I.); Schoen Klinik Bad Aibling, Bad Aibling, Germany (C.L.); Stroke Service, Poole Hospital, Poole, United Kingdom (S.R.); Neurology Clinic, Bad Neustadt, Germany (H.S.); Acute Stroke Unit, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom (A.W.); Unité de la voix et de la deglutition, Service ORL CHU de Toulouse, Octogone Lordat Université Toulouse Mirail, France (V.W.); and Centre for Gastrointestinal Sciences, University of Manchester, United Kingdom (S.H.)
| | - Anushka Warusevitane
- From the Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B., P.S.); Phagenesis, Ltd, Manchester Science Park, United Kingdom (J.L.); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Hospital de Mataró, Universitat Autònoma de Mataró, Spain (P.C.); Stroke Service, Northwick Park Hospital, London, United Kingdom (D.C.); Department of Neurology, University Hospital Münster, Germany (R.D.); Department of Neurology, Glostrup Hospital and University of Copenhagen, Denmark (H.K.I.); Schoen Klinik Bad Aibling, Bad Aibling, Germany (C.L.); Stroke Service, Poole Hospital, Poole, United Kingdom (S.R.); Neurology Clinic, Bad Neustadt, Germany (H.S.); Acute Stroke Unit, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom (A.W.); Unité de la voix et de la deglutition, Service ORL CHU de Toulouse, Octogone Lordat Université Toulouse Mirail, France (V.W.); and Centre for Gastrointestinal Sciences, University of Manchester, United Kingdom (S.H.)
| | - Virginie Woisard
- From the Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B., P.S.); Phagenesis, Ltd, Manchester Science Park, United Kingdom (J.L.); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Hospital de Mataró, Universitat Autònoma de Mataró, Spain (P.C.); Stroke Service, Northwick Park Hospital, London, United Kingdom (D.C.); Department of Neurology, University Hospital Münster, Germany (R.D.); Department of Neurology, Glostrup Hospital and University of Copenhagen, Denmark (H.K.I.); Schoen Klinik Bad Aibling, Bad Aibling, Germany (C.L.); Stroke Service, Poole Hospital, Poole, United Kingdom (S.R.); Neurology Clinic, Bad Neustadt, Germany (H.S.); Acute Stroke Unit, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom (A.W.); Unité de la voix et de la deglutition, Service ORL CHU de Toulouse, Octogone Lordat Université Toulouse Mirail, France (V.W.); and Centre for Gastrointestinal Sciences, University of Manchester, United Kingdom (S.H.)
| | - Shaheen Hamdy
- From the Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B., P.S.); Phagenesis, Ltd, Manchester Science Park, United Kingdom (J.L.); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Hospital de Mataró, Universitat Autònoma de Mataró, Spain (P.C.); Stroke Service, Northwick Park Hospital, London, United Kingdom (D.C.); Department of Neurology, University Hospital Münster, Germany (R.D.); Department of Neurology, Glostrup Hospital and University of Copenhagen, Denmark (H.K.I.); Schoen Klinik Bad Aibling, Bad Aibling, Germany (C.L.); Stroke Service, Poole Hospital, Poole, United Kingdom (S.R.); Neurology Clinic, Bad Neustadt, Germany (H.S.); Acute Stroke Unit, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom (A.W.); Unité de la voix et de la deglutition, Service ORL CHU de Toulouse, Octogone Lordat Université Toulouse Mirail, France (V.W.); and Centre for Gastrointestinal Sciences, University of Manchester, United Kingdom (S.H.)
| | | |
Collapse
|
115
|
Cohen DL, Roffe C, Beavan J, Blackett B, Fairfield CA, Hamdy S, Havard D, McFarlane M, McLauglin C, Randall M, Robson K, Scutt P, Smith C, Smithard D, Sprigg N, Warusevitane A, Watkins C, Woodhouse L, Bath PM. Post-stroke dysphagia: A review and design considerations for future trials. Int J Stroke 2016; 11:399-411. [PMID: 27006423 DOI: 10.1177/1747493016639057] [Citation(s) in RCA: 271] [Impact Index Per Article: 30.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2015] [Accepted: 12/21/2015] [Indexed: 12/14/2022]
Abstract
Post-stroke dysphagia (a difficulty in swallowing after a stroke) is a common and expensive complication of acute stroke and is associated with increased mortality, morbidity, and institutionalization due in part to aspiration, pneumonia, and malnutrition. Although most patients recover swallowing spontaneously, a significant minority still have dysphagia at six months. Although multiple advances have been made in the hyperacute treatment of stroke and secondary prevention, the management of dysphagia post-stroke remains a neglected area of research, and its optimal management, including diagnosis, investigation and treatment, have still to be defined.
Collapse
Affiliation(s)
| | - Christine Roffe
- Stroke Research, University Hospital of North Midlands, Keele University, UK
| | | | | | - Carol A Fairfield
- School of Psychology and Clinical Language Sciences, University of Reading, UK
| | - Shaheen Hamdy
- Institute of Inflammation and Repair, University of Manchester, UK
| | - Di Havard
- Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, UK
| | | | | | | | - Katie Robson
- Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, UK
| | - Polly Scutt
- Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, UK
| | - Craig Smith
- Stroke and Vascular Research Centre, University of Manchester, UK
| | - David Smithard
- Elderly Medicine, Princess Royal University Hospital, UK
| | - Nikola Sprigg
- Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, UK
| | | | - Caroline Watkins
- College of Health and Wellbeing, University of Central Lancashire, UK
| | - Lisa Woodhouse
- Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, UK
| | - Philip M Bath
- Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, UK
| |
Collapse
|
116
|
Warusevitane A, Karunatilake D, Sim J, Smith C, Roffe C. Early Diagnosis of Pneumonia in Severe Stroke: Clinical Features and the Diagnostic Role of C-Reactive Protein. PLoS One 2016; 11:e0150269. [PMID: 26937636 PMCID: PMC4777448 DOI: 10.1371/journal.pone.0150269] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Accepted: 02/11/2016] [Indexed: 11/25/2022] Open
Abstract
Background Accurate diagnosis of pneumonia complicating severe stroke is challenging due to difficulties in physical examination, altered immune responses and delayed manifestations of radiological changes. The aims of this study were to describe early clinical features and to examine C-reactive protein (CRP) as a diagnostic marker of post-stroke pneumonia. Methods Patients who required nasogastric feeding and had no evidence of pneumonia within 7 days of stroke onset were included in the study and followed-up for 21 days with a daily clinical examination. Pneumonia was diagnosed using modified British Thoracic Society criteria. Results 60 patients were recruited (mean age 77 years, mean National Institutes of Health Stroke Scale Score 19.47). Forty-four episodes of pneumonia were identified. Common manifestations on the day of the diagnosis were new onset crackles (43/44, 98%), tachypnoea>25/min (42/44, 95%), and oxygen saturation <90% (41/44, 93%). Cough, purulent sputum, and pyrexia >38°C were observed in 27 (61%), 25 (57%) and 15 (34%) episodes respectively. Leucocytosis (WBC>11,000/ml) and raised CRP (>10 mg/l) were observed in 38 (86%) and 43 (97%) cases of pneumonia respectively. The area under the ROC curve for CRP was 0.827 (95% CI 0.720, 0.933). The diagnostic cut-off for CRP with an acceptable sensitivity (>0.8) was 25.60 mg/L (Youden index (J) 0.515; sensitivity 0.848; specificity 0.667). A cut-off of 64.65 mg/L had the highest diagnostic accuracy (J 0.562; sensitivity 0.636; specificity 0.926). Conclusion Patients with severe stroke frequently do not manifest key diagnostic features of pneumonia such as pyrexia, cough and purulent sputum early in their illness. The most common signs in this group are new-onset crackles, tachypnoea and hypoxia. Our results suggest that a CRP >25 mg/L should prompt investigations for pneumonia while values >65 mg/L have the highest diagnostic accuracy to justify consideration of this threshold as a diagnostic marker of post-stroke pneumonia.
Collapse
Affiliation(s)
- Anushka Warusevitane
- Stoke Stroke Research Group, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom
- * E-mail:
| | | | - Julius Sim
- Health Services Research Unit, Keele University, Stoke-on-Trent, United Kingdom
| | - Craig Smith
- Stroke and Vascular Research Centre, University of Manchester, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
| | - Christine Roffe
- Stoke Stroke Research Group, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom
- Health Services Research Unit, Keele University, Stoke-on-Trent, United Kingdom
| |
Collapse
|
117
|
Kalra L, Irshad S, Hodsoll J, Simpson M, Gulliford M, Smithard D, Patel A, Rebollo-Mesa I. Prophylactic antibiotics after acute stroke for reducing pneumonia in patients with dysphagia (STROKE-INF): a prospective, cluster-randomised, open-label, masked endpoint, controlled clinical trial. Lancet 2015; 386:1835-44. [PMID: 26343840 DOI: 10.1016/s0140-6736(15)00126-9] [Citation(s) in RCA: 191] [Impact Index Per Article: 19.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Post-stroke pneumonia is associated with increased mortality and poor functional outcomes. This study assessed the effectiveness of antibiotic prophylaxis for reducing pneumonia in patients with dysphagia after acute stroke. METHODS We did a prospective, multicentre, cluster-randomised, open-label controlled trial with masked endpoint assessment of patients older than 18 years with dysphagia after new stroke recruited from 48 stroke units in the UK, accredited and included in the UK National Stroke Audit. We excluded patients with contraindications to antibiotics, pre-existing dysphagia, or known infections, or who were not expected to survive beyond 14 days. We randomly assigned the units (1:1) by computer to give either prophylactic antibiotics for 7 days plus standard stroke unit care or standard stroke unit care only to patients clustered in the units within 48 h of stroke onset. We did the randomisation with minimisation to stratify for number of admissions and access to specialist care. Patient and staff who did the assessments and analyses were masked to stroke unit allocation. The primary outcome was post-stroke pneumonia in the first 14 days, assessed with both a criteria-based, hierarchical algorithm and by physician diagnosis in the intention-to-treat population. Safety was also analysed by intention to treat. This trial is closed to new participants and is registered with isrctn.com, number ISRCTN37118456. FINDINGS Between April 21, 2008, and May 17, 2014, we randomly assigned 48 stroke units (and 1224 patients clustered within the units) to the two treatment groups: 24 to antibiotics and 24 to standard care alone (control). 11 units and seven patients withdrew after randomisation before 14 days, leaving 1217 patients in 37 units for the intention-to-treat analysis (615 patients in the antibiotics group, 602 in control). Prophylactic antibiotics did not affect the incidence of algorithm-defined post-stroke pneumonia (71 [13%] of 564 patients in antibiotics group vs 52 [10%] of 524 in control group; marginal adjusted odds ratio [OR] 1·21 [95% CI 0·71-2·08], p=0·489, intraclass correlation coefficient [ICC] 0·06 [95% CI 0·02-0·17]. Algorithm-defined post-stroke pneumonia could not be established in 129 (10%) patients because of missing data. Additionally, we noted no differences in physician-diagnosed post-stroke pneumonia between groups (101 [16%] of 615 patients vs 91 [15%] of 602, adjusted OR 1·01 [95% CI 0·61-1·68], p=0·957, ICC 0·08 [95% CI 0·03-0·21]). The most common adverse events were infections unrelated to post-stroke pneumonia (mainly urinary tract infections), which were less frequent in the antibiotics group (22 [4%] of 615 vs 45 [7%] of 602; OR 0·55 [0·32-0·92], p=0·02). Diarrhoea positive for Clostridium difficile occurred in two patients (<1%) in the antibiotics group and four (<1%) in the control group, and meticillin-resistant Staphylococcus aureus colonisation occurred in 11 patients (2%) in the antibiotics group and 14 (2%) in the control group. INTERPRETATION Antibiotic prophylaxis cannot be recommended for prevention of post-stroke pneumonia in patients with dysphagia after stroke managed in stroke units. FUNDING UK National Institute for Health Research.
Collapse
Affiliation(s)
- Lalit Kalra
- Department of Basic and Clinical Neurosciences, Institute of Psychiatry, Psychology and Neurosciences, King's College London, London, UK.
| | - Saddif Irshad
- Department of Basic and Clinical Neurosciences, Institute of Psychiatry, Psychology and Neurosciences, King's College London, London, UK
| | - John Hodsoll
- King's Clinical Trials Unit, Biostatistics Department, Institute of Psychiatry, Psychology and Neurosciences, King's College London, London, UK; UK and NIHR Biomedical Research Centre for Mental Health, South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Matthew Simpson
- UK Joint Clinical Trials Office, The King's Health Partners, Guy's and St Thomas' Hospital, London, UK
| | - Martin Gulliford
- Division of Health and Social Care Research, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | | | - Anita Patel
- Centre for the Economics of Mental and Physical Health, Institute of Psychiatry, Psychology and Neurosciences, King's College London, London, UK
| | - Irene Rebollo-Mesa
- King's Clinical Trials Unit, Biostatistics Department, Institute of Psychiatry, Psychology and Neurosciences, King's College London, London, UK
| |
Collapse
|
118
|
Affiliation(s)
- Andreas Meisel
- NeuroCure Clinical Research Center, Center for Stroke Research Berlin, Department of Neurology, Charité Universitaetsmedizin Berlin, D-10117 Berlin, Germany.
| | - Craig J Smith
- Centre for Stroke and Vascular Research, Salford Royal Hospital NHS Foundation Trust, Salford, UK
| |
Collapse
|
119
|
|
120
|
Smith CJ, Kishore AK, Vail A, Chamorro A, Garau J, Hopkins SJ, Di Napoli M, Kalra L, Langhorne P, Montaner J, Roffe C, Rudd AG, Tyrrell PJ, van de Beek D, Woodhead M, Meisel A. Diagnosis of Stroke-Associated Pneumonia. Stroke 2015; 46:2335-40. [DOI: 10.1161/strokeaha.115.009617] [Citation(s) in RCA: 193] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Accepted: 05/22/2015] [Indexed: 01/03/2023]
Abstract
Background and Purpose—
Lower respiratory tract infections frequently complicate stroke and adversely affect outcome. There is currently no agreed terminology or gold-standard diagnostic criteria for the spectrum of lower respiratory tract infections complicating stroke, which has implications for clinical practice and research. The aim of this consensus was to propose standardized terminology and operational diagnostic criteria for lower respiratory tract infections complicating acute stroke.
Methods—
Systematic literature searches of multiple electronic databases were undertaken. An evidence review and 2 rounds of consensus consultation were completed before a final consensus meeting in September 2014, held in Manchester, United Kingdom. Consensus was defined a priori as ≥75% agreement between the consensus group members.
Results—
Consensus was reached for the following: (1) stroke-associated pneumonia (SAP) is the recommended terminology for the spectrum of lower respiratory tract infections within the first 7 days after stroke onset; (2) modified Centers for Disease Control and Prevention (CDC) criteria are proposed for SAP as follows—probable SAP: CDC criteria met, but typical chest x-ray changes absent even after repeat or serial chest x-ray; definite SAP: CDC criteria met, including typical chest x-ray changes; (3) there is limited evidence for a diagnostic role of white blood cell count or C-reactive protein in SAP; and (4) there is insufficient evidence for the use of other biomarkers (eg, procalcitonin).
Conclusions—
Consensus operational criteria for the terminology and diagnosis of SAP are proposed based on the CDC criteria. These require prospective evaluation in patients with stroke to determine their reliability, validity, impact on clinician behaviors (including antibiotic prescribing), and clinical outcomes.
Collapse
Affiliation(s)
- Craig J. Smith
- From the Stroke and Vascular Research Centre (C.J.S., A.K.K., S.J.H., P.J.T.) and Centre for Biostatistics (A.V.), University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, Salford, United Kingdom; Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain (A.C.); Department of Medicine, Hospital Universitari Mutua de Terrassa, Barcelona, Spain (J.G.); Neurological Service, San Camillo de’ Lellis
| | - Amit K. Kishore
- From the Stroke and Vascular Research Centre (C.J.S., A.K.K., S.J.H., P.J.T.) and Centre for Biostatistics (A.V.), University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, Salford, United Kingdom; Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain (A.C.); Department of Medicine, Hospital Universitari Mutua de Terrassa, Barcelona, Spain (J.G.); Neurological Service, San Camillo de’ Lellis
| | - Andy Vail
- From the Stroke and Vascular Research Centre (C.J.S., A.K.K., S.J.H., P.J.T.) and Centre for Biostatistics (A.V.), University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, Salford, United Kingdom; Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain (A.C.); Department of Medicine, Hospital Universitari Mutua de Terrassa, Barcelona, Spain (J.G.); Neurological Service, San Camillo de’ Lellis
| | - Angel Chamorro
- From the Stroke and Vascular Research Centre (C.J.S., A.K.K., S.J.H., P.J.T.) and Centre for Biostatistics (A.V.), University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, Salford, United Kingdom; Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain (A.C.); Department of Medicine, Hospital Universitari Mutua de Terrassa, Barcelona, Spain (J.G.); Neurological Service, San Camillo de’ Lellis
| | - Javier Garau
- From the Stroke and Vascular Research Centre (C.J.S., A.K.K., S.J.H., P.J.T.) and Centre for Biostatistics (A.V.), University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, Salford, United Kingdom; Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain (A.C.); Department of Medicine, Hospital Universitari Mutua de Terrassa, Barcelona, Spain (J.G.); Neurological Service, San Camillo de’ Lellis
| | - Stephen J. Hopkins
- From the Stroke and Vascular Research Centre (C.J.S., A.K.K., S.J.H., P.J.T.) and Centre for Biostatistics (A.V.), University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, Salford, United Kingdom; Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain (A.C.); Department of Medicine, Hospital Universitari Mutua de Terrassa, Barcelona, Spain (J.G.); Neurological Service, San Camillo de’ Lellis
| | - Mario Di Napoli
- From the Stroke and Vascular Research Centre (C.J.S., A.K.K., S.J.H., P.J.T.) and Centre for Biostatistics (A.V.), University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, Salford, United Kingdom; Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain (A.C.); Department of Medicine, Hospital Universitari Mutua de Terrassa, Barcelona, Spain (J.G.); Neurological Service, San Camillo de’ Lellis
| | - Lalit Kalra
- From the Stroke and Vascular Research Centre (C.J.S., A.K.K., S.J.H., P.J.T.) and Centre for Biostatistics (A.V.), University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, Salford, United Kingdom; Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain (A.C.); Department of Medicine, Hospital Universitari Mutua de Terrassa, Barcelona, Spain (J.G.); Neurological Service, San Camillo de’ Lellis
| | - Peter Langhorne
- From the Stroke and Vascular Research Centre (C.J.S., A.K.K., S.J.H., P.J.T.) and Centre for Biostatistics (A.V.), University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, Salford, United Kingdom; Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain (A.C.); Department of Medicine, Hospital Universitari Mutua de Terrassa, Barcelona, Spain (J.G.); Neurological Service, San Camillo de’ Lellis
| | - Joan Montaner
- From the Stroke and Vascular Research Centre (C.J.S., A.K.K., S.J.H., P.J.T.) and Centre for Biostatistics (A.V.), University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, Salford, United Kingdom; Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain (A.C.); Department of Medicine, Hospital Universitari Mutua de Terrassa, Barcelona, Spain (J.G.); Neurological Service, San Camillo de’ Lellis
| | - Christine Roffe
- From the Stroke and Vascular Research Centre (C.J.S., A.K.K., S.J.H., P.J.T.) and Centre for Biostatistics (A.V.), University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, Salford, United Kingdom; Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain (A.C.); Department of Medicine, Hospital Universitari Mutua de Terrassa, Barcelona, Spain (J.G.); Neurological Service, San Camillo de’ Lellis
| | - Anthony G. Rudd
- From the Stroke and Vascular Research Centre (C.J.S., A.K.K., S.J.H., P.J.T.) and Centre for Biostatistics (A.V.), University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, Salford, United Kingdom; Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain (A.C.); Department of Medicine, Hospital Universitari Mutua de Terrassa, Barcelona, Spain (J.G.); Neurological Service, San Camillo de’ Lellis
| | - Pippa J. Tyrrell
- From the Stroke and Vascular Research Centre (C.J.S., A.K.K., S.J.H., P.J.T.) and Centre for Biostatistics (A.V.), University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, Salford, United Kingdom; Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain (A.C.); Department of Medicine, Hospital Universitari Mutua de Terrassa, Barcelona, Spain (J.G.); Neurological Service, San Camillo de’ Lellis
| | - Diederik van de Beek
- From the Stroke and Vascular Research Centre (C.J.S., A.K.K., S.J.H., P.J.T.) and Centre for Biostatistics (A.V.), University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, Salford, United Kingdom; Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain (A.C.); Department of Medicine, Hospital Universitari Mutua de Terrassa, Barcelona, Spain (J.G.); Neurological Service, San Camillo de’ Lellis
| | - Mark Woodhead
- From the Stroke and Vascular Research Centre (C.J.S., A.K.K., S.J.H., P.J.T.) and Centre for Biostatistics (A.V.), University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, Salford, United Kingdom; Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain (A.C.); Department of Medicine, Hospital Universitari Mutua de Terrassa, Barcelona, Spain (J.G.); Neurological Service, San Camillo de’ Lellis
| | - Andreas Meisel
- From the Stroke and Vascular Research Centre (C.J.S., A.K.K., S.J.H., P.J.T.) and Centre for Biostatistics (A.V.), University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, Salford, United Kingdom; Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain (A.C.); Department of Medicine, Hospital Universitari Mutua de Terrassa, Barcelona, Spain (J.G.); Neurological Service, San Camillo de’ Lellis
| |
Collapse
|
121
|
Affiliation(s)
- Stefan Tino Kulnik
- From the Department of Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK.
| |
Collapse
|
122
|
Affiliation(s)
- Irene L Katzan
- From the Neurological Institute Center for Outcomes Research and Evaluation, Cleveland Clinic, OH.
| |
Collapse
|